Insys' Sublingual Buprenorphine Spray Fails At US FDA Panel, But Some Members See Future In Limited Role
Executive Summary
Main concerns involved the delayed onset to meaningful pain relief and the safety signal of hypoxia.
You may also be interested in...
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Insys May Need Convenience Argument To Save Sublingual Buprenorphine Spray
US FDA advisory committee will hear agency's concerns with Buvaya's effectiveness, safety, and abuse potential.